img

Global Relapsing-Remitting Multiple Sclerosis Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Relapsing-Remitting Multiple Sclerosis Market Insights, Forecast to 2034

Relapsing-remitting multiple sclerosis (RRMS) is a specific subtype of multiple sclerosis (MS), which is a chronic autoimmune neurological disorder that affects the central nervous system (CNS). RRMS is the most common form of MS and is characterized by distinct periods of symptom flare-ups (relapses) followed by periods of partial or complete recovery (remissions). During relapses, new symptoms or the worsening of existing symptoms may occur, while remissions involve a reduction in symptoms or their temporary disappearance.
Market Analysis and InsightsGlobal Relapsing-Remitting Multiple Sclerosis Market
Global Relapsing-Remitting Multiple Sclerosis market is expected to reach to US$ 4892.1 million in 2023, with a positive growth of %, compared with US$ 4702.2 million in 2022. Backed with the increasing demand from downstream industries, Relapsing-Remitting Multiple Sclerosis industry is evaluated to reach US$ 5875.5 million in 2033. The CAGR will be 3.1% during 2023 to 2033.
The RRMS treatment landscape was seeing continuous advancements in the development of new disease-modifying therapies. These therapies aimed to provide more targeted and effective options for reducing relapses, managing symptoms, and slowing disease progression. Some newer therapies were exploring novel mechanisms of action to better control inflammation and immune responses.
Report Covers
This report presents an overview of global Relapsing-Remitting Multiple Sclerosis market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Relapsing-Remitting Multiple Sclerosis market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Biogen
Novartis
Roche
Bayer HealthCare
Pfizer
Merck & Co., Inc
Sanofi
Teva Pharmaceutical Industries
GlaxoSmithKline
Acorda Therapeutics
Actelion Pharmaceuticals (Johnson & Johnson)
AbbVie
CinnoVex
Extavia
Tysabr
Segment by Type
Oral
Intravenous Injection

Segment by Application


Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Relapsing-Remitting Multiple Sclerosis introduction, etc. Relapsing-Remitting Multiple Sclerosis Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Relapsing-Remitting Multiple Sclerosis
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Oral
1.2.3 Intravenous Injection
1.3 Market by Application
1.3.1 Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Relapsing-Remitting Multiple Sclerosis Market Perspective (2018-2033)
2.2 Global Relapsing-Remitting Multiple Sclerosis Growth Trends by Region
2.2.1 Relapsing-Remitting Multiple Sclerosis Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Relapsing-Remitting Multiple Sclerosis Historic Market Size by Region (2018-2023)
2.2.3 Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Region (2024-2033)
2.3 Relapsing-Remitting Multiple Sclerosis Market Dynamics
2.3.1 Relapsing-Remitting Multiple Sclerosis Industry Trends
2.3.2 Relapsing-Remitting Multiple Sclerosis Market Drivers
2.3.3 Relapsing-Remitting Multiple Sclerosis Market Challenges
2.3.4 Relapsing-Remitting Multiple Sclerosis Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Relapsing-Remitting Multiple Sclerosis by Players
3.1.1 Global Relapsing-Remitting Multiple Sclerosis Revenue by Players (2018-2023)
3.1.2 Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Players (2018-2023)
3.2 Global Relapsing-Remitting Multiple Sclerosis Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Relapsing-Remitting Multiple Sclerosis, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Relapsing-Remitting Multiple Sclerosis Market Concentration Ratio
3.4.1 Global Relapsing-Remitting Multiple Sclerosis Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Relapsing-Remitting Multiple Sclerosis Revenue in 2022
3.5 Global Key Players of Relapsing-Remitting Multiple Sclerosis Head office and Area Served
3.6 Global Key Players of Relapsing-Remitting Multiple Sclerosis, Product and Application
3.7 Global Key Players of Relapsing-Remitting Multiple Sclerosis, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Relapsing-Remitting Multiple Sclerosis Breakdown Data by Type
4.1 Global Relapsing-Remitting Multiple Sclerosis Historic Market Size by Type (2018-2023)
4.2 Global Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Type (2024-2033)
5 Relapsing-Remitting Multiple Sclerosis Breakdown Data by Application
5.1 Global Relapsing-Remitting Multiple Sclerosis Historic Market Size by Application (2018-2023)
5.2 Global Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Relapsing-Remitting Multiple Sclerosis Market Size (2018-2033)
6.2 North America Relapsing-Remitting Multiple Sclerosis Market Size by Type
6.2.1 North America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
6.2.2 North America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033)
6.2.3 North America Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
6.3 North America Relapsing-Remitting Multiple Sclerosis Market Size by Application
6.3.1 North America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
6.3.2 North America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033)
6.3.3 North America Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
6.4 North America Relapsing-Remitting Multiple Sclerosis Market Size by Country
6.4.1 North America Relapsing-Remitting Multiple Sclerosis Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023)
6.4.3 North America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Relapsing-Remitting Multiple Sclerosis Market Size (2018-2033)
7.2 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type
7.2.1 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
7.2.2 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033)
7.2.3 Europe Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
7.3 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application
7.3.1 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
7.3.2 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033)
7.3.3 Europe Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
7.4 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country
7.4.1 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023)
7.4.3 Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Relapsing-Remitting Multiple Sclerosis Market Size (2018-2033)
8.2 China Relapsing-Remitting Multiple Sclerosis Market Size by Type
8.2.1 China Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
8.2.2 China Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033)
8.2.3 China Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
8.3 China Relapsing-Remitting Multiple Sclerosis Market Size by Application
8.3.1 China Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
8.3.2 China Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033)
8.3.3 China Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Relapsing-Remitting Multiple Sclerosis Market Size (2018-2033)
9.2 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Type
9.2.1 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
9.2.2 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033)
9.2.3 Asia Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
9.3 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Application
9.3.1 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
9.3.2 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033)
9.3.3 Asia Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
9.4 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region
9.4.1 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023)
9.4.3 Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Type
10.2.1 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Application
10.3.1 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country
10.4.1 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Relapsing-Remitting Multiple Sclerosis Introduction
11.1.4 Biogen Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.1.5 Biogen Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Relapsing-Remitting Multiple Sclerosis Introduction
11.2.4 Novartis Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.2.5 Novartis Recent Developments
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Relapsing-Remitting Multiple Sclerosis Introduction
11.3.4 Roche Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.3.5 Roche Recent Developments
11.4 Bayer HealthCare
11.4.1 Bayer HealthCare Company Details
11.4.2 Bayer HealthCare Business Overview
11.4.3 Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Introduction
11.4.4 Bayer HealthCare Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.4.5 Bayer HealthCare Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Relapsing-Remitting Multiple Sclerosis Introduction
11.5.4 Pfizer Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.5.5 Pfizer Recent Developments
11.6 Merck & Co., Inc
11.6.1 Merck & Co., Inc Company Details
11.6.2 Merck & Co., Inc Business Overview
11.6.3 Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Introduction
11.6.4 Merck & Co., Inc Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.6.5 Merck & Co., Inc Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Relapsing-Remitting Multiple Sclerosis Introduction
11.7.4 Sanofi Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.7.5 Sanofi Recent Developments
11.8 Teva Pharmaceutical Industries
11.8.1 Teva Pharmaceutical Industries Company Details
11.8.2 Teva Pharmaceutical Industries Business Overview
11.8.3 Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Introduction
11.8.4 Teva Pharmaceutical Industries Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.8.5 Teva Pharmaceutical Industries Recent Developments
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Details
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Introduction
11.9.4 GlaxoSmithKline Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.9.5 GlaxoSmithKline Recent Developments
11.10 Acorda Therapeutics
11.10.1 Acorda Therapeutics Company Details
11.10.2 Acorda Therapeutics Business Overview
11.10.3 Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Introduction
11.10.4 Acorda Therapeutics Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.10.5 Acorda Therapeutics Recent Developments
11.11 Actelion Pharmaceuticals (Johnson & Johnson)
11.11.1 Actelion Pharmaceuticals (Johnson & Johnson) Company Details
11.11.2 Actelion Pharmaceuticals (Johnson & Johnson) Business Overview
11.11.3 Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Introduction
11.11.4 Actelion Pharmaceuticals (Johnson & Johnson) Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.11.5 Actelion Pharmaceuticals (Johnson & Johnson) Recent Developments
11.12 AbbVie
11.12.1 AbbVie Company Details
11.12.2 AbbVie Business Overview
11.12.3 AbbVie Relapsing-Remitting Multiple Sclerosis Introduction
11.12.4 AbbVie Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.12.5 AbbVie Recent Developments
11.13 CinnoVex
11.13.1 CinnoVex Company Details
11.13.2 CinnoVex Business Overview
11.13.3 CinnoVex Relapsing-Remitting Multiple Sclerosis Introduction
11.13.4 CinnoVex Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.13.5 CinnoVex Recent Developments
11.14 Extavia
11.14.1 Extavia Company Details
11.14.2 Extavia Business Overview
11.14.3 Extavia Relapsing-Remitting Multiple Sclerosis Introduction
11.14.4 Extavia Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.14.5 Extavia Recent Developments
11.15 Tysabr
11.15.1 Tysabr Company Details
11.15.2 Tysabr Business Overview
11.15.3 Tysabr Relapsing-Remitting Multiple Sclerosis Introduction
11.15.4 Tysabr Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
11.15.5 Tysabr Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Oral
Table 3. Key Players of Intravenous Injection
Table 4. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 5. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Relapsing-Remitting Multiple Sclerosis Market Share by Region (2018-2023)
Table 8. Global Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Relapsing-Remitting Multiple Sclerosis Market Share by Region (2024-2033)
Table 10. Relapsing-Remitting Multiple Sclerosis Market Trends
Table 11. Relapsing-Remitting Multiple Sclerosis Market Drivers
Table 12. Relapsing-Remitting Multiple Sclerosis Market Challenges
Table 13. Relapsing-Remitting Multiple Sclerosis Market Restraints
Table 14. Global Relapsing-Remitting Multiple Sclerosis Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Relapsing-Remitting Multiple Sclerosis Revenue Share by Players (2018-2023)
Table 16. Global Top Relapsing-Remitting Multiple Sclerosis by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Relapsing-Remitting Multiple Sclerosis as of 2022)
Table 17. Global Relapsing-Remitting Multiple Sclerosis Industry Ranking 2021 VS 2022 VS 2023
Table 18. Global 5 Largest Players Market Share by Relapsing-Remitting Multiple Sclerosis Revenue (CR5 and HHI) & (2018-2023)
Table 19. Global Key Players of Relapsing-Remitting Multiple Sclerosis, Headquarters and Area Served
Table 20. Global Key Players of Relapsing-Remitting Multiple Sclerosis, Product and Application
Table 21. Global Key Players of Relapsing-Remitting Multiple Sclerosis, Product and Application
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Type (2018-2023)
Table 25. Global Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Relapsing-Remitting Multiple Sclerosis Revenue Market Share by Type (2024-2033)
Table 27. Global Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Relapsing-Remitting Multiple Sclerosis Revenue Share by Application (2018-2023)
Table 29. Global Relapsing-Remitting Multiple Sclerosis Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Relapsing-Remitting Multiple Sclerosis Revenue Share by Application (2024-2033)
Table 31. North America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 32. North America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033) & (US$ Million)
Table 33. North America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 34. North America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033) & (US$ Million)
Table 35. North America Relapsing-Remitting Multiple Sclerosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. North America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033) & (US$ Million)
Table 38. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 39. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033) & (US$ Million)
Table 40. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 41. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033) & (US$ Million)
Table 42. Europe Relapsing-Remitting Multiple Sclerosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 43. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023) & (US$ Million)
Table 44. Europe Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033) & (US$ Million)
Table 45. China Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 46. China Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033) & (US$ Million)
Table 47. China Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 48. China Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033) & (US$ Million)
Table 49. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 50. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033) & (US$ Million)
Table 51. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 52. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033) & (US$ Million)
Table 53. Asia Relapsing-Remitting Multiple Sclerosis Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 54. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region (2018-2023) & (US$ Million)
Table 55. Asia Relapsing-Remitting Multiple Sclerosis Market Size by Region (2024-2033) & (US$ Million)
Table 56. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2018-2023) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Type (2024-2033) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2018-2023) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Application (2024-2033) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 61. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2018-2023) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size by Country (2024-2033) & (US$ Million)
Table 63. Biogen Company Details
Table 64. Biogen Business Overview
Table 65. Biogen Relapsing-Remitting Multiple Sclerosis Product
Table 66. Biogen Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 67. Biogen Recent Developments
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Relapsing-Remitting Multiple Sclerosis Product
Table 71. Novartis Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 72. Novartis Recent Developments
Table 73. Roche Company Details
Table 74. Roche Business Overview
Table 75. Roche Relapsing-Remitting Multiple Sclerosis Product
Table 76. Roche Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 77. Roche Recent Developments
Table 78. Bayer HealthCare Company Details
Table 79. Bayer HealthCare Business Overview
Table 80. Bayer HealthCare Relapsing-Remitting Multiple Sclerosis Product
Table 81. Bayer HealthCare Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 82. Bayer HealthCare Recent Developments
Table 83. Pfizer Company Details
Table 84. Pfizer Business Overview
Table 85. Pfizer Relapsing-Remitting Multiple Sclerosis Product
Table 86. Pfizer Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 87. Pfizer Recent Developments
Table 88. Merck & Co., Inc Company Details
Table 89. Merck & Co., Inc Business Overview
Table 90. Merck & Co., Inc Relapsing-Remitting Multiple Sclerosis Product
Table 91. Merck & Co., Inc Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 92. Merck & Co., Inc Recent Developments
Table 93. Sanofi Company Details
Table 94. Sanofi Business Overview
Table 95. Sanofi Relapsing-Remitting Multiple Sclerosis Product
Table 96. Sanofi Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 97. Sanofi Recent Developments
Table 98. Teva Pharmaceutical Industries Company Details
Table 99. Teva Pharmaceutical Industries Business Overview
Table 100. Teva Pharmaceutical Industries Relapsing-Remitting Multiple Sclerosis Product
Table 101. Teva Pharmaceutical Industries Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 102. Teva Pharmaceutical Industries Recent Developments
Table 103. GlaxoSmithKline Company Details
Table 104. GlaxoSmithKline Business Overview
Table 105. GlaxoSmithKline Relapsing-Remitting Multiple Sclerosis Product
Table 106. GlaxoSmithKline Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 107. GlaxoSmithKline Recent Developments
Table 108. Acorda Therapeutics Company Details
Table 109. Acorda Therapeutics Business Overview
Table 110. Acorda Therapeutics Relapsing-Remitting Multiple Sclerosis Product
Table 111. Acorda Therapeutics Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 112. Acorda Therapeutics Recent Developments
Table 113. Actelion Pharmaceuticals (Johnson & Johnson) Company Details
Table 114. Actelion Pharmaceuticals (Johnson & Johnson) Business Overview
Table 115. Actelion Pharmaceuticals (Johnson & Johnson) Relapsing-Remitting Multiple Sclerosis Product
Table 116. Actelion Pharmaceuticals (Johnson & Johnson) Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 117. Actelion Pharmaceuticals (Johnson & Johnson) Recent Developments
Table 118. AbbVie Company Details
Table 119. AbbVie Business Overview
Table 120. AbbVie Relapsing-Remitting Multiple Sclerosis Product
Table 121. AbbVie Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 122. AbbVie Recent Developments
Table 123. CinnoVex Company Details
Table 124. CinnoVex Business Overview
Table 125. CinnoVex Relapsing-Remitting Multiple Sclerosis Product
Table 126. CinnoVex Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 127. CinnoVex Recent Developments
Table 128. Extavia Company Details
Table 129. Extavia Business Overview
Table 130. Extavia Relapsing-Remitting Multiple Sclerosis Product
Table 131. Extavia Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 132. Extavia Recent Developments
Table 133. Tysabr Company Details
Table 134. Tysabr Business Overview
Table 135. Tysabr Relapsing-Remitting Multiple Sclerosis Product
Table 136. Tysabr Revenue in Relapsing-Remitting Multiple Sclerosis Business (2018-2023) & (US$ Million)
Table 137. Tysabr Recent Developments
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Relapsing-Remitting Multiple Sclerosis Market Share by Type: 2022 VS 2033
Figure 3. Oral Features
Figure 4. Intravenous Injection Features
Figure 5. Global Relapsing-Remitting Multiple Sclerosis Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 6. Global Relapsing-Remitting Multiple Sclerosis Market Share by Application: 2022 VS 2033
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Relapsing-Remitting Multiple Sclerosis Report Years Considered
Figure 10. Global Relapsing-Remitting Multiple Sclerosis Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 11. Global Relapsing-Remitting Multiple Sclerosis Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 12. Global Relapsing-Remitting Multiple Sclerosis Market Share by Region: 2022 VS 2033
Figure 13. Global Relapsing-Remitting Multiple Sclerosis Market Share by Players in 2022
Figure 14. Global Top Relapsing-Remitting Multiple Sclerosis Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Relapsing-Remitting Multiple Sclerosis as of 2022)
Figure 15. The Top 10 and 5 Players Market Share by Relapsing-Remitting Multiple Sclerosis Revenue in 2022
Figure 16. North America Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 17. North America Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
Figure 18. North America Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
Figure 19. North America Relapsing-Remitting Multiple Sclerosis Market Share by Country (2018-2033)
Figure 20. United States Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Relapsing-Remitting Multiple Sclerosis Market Size YoY (2018-2033) & (US$ Million)
Figure 23. Europe Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
Figure 24. Europe Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
Figure 25. Europe Relapsing-Remitting Multiple Sclerosis Market Share by Country (2018-2033)
Figure 26. Germany Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. China Relapsing-Remitting Multiple Sclerosis Market Size YoY (2018-2033) & (US$ Million)
Figure 33. China Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
Figure 34. China Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
Figure 35. Asia Relapsing-Remitting Multiple Sclerosis Market Size YoY (2018-2033) & (US$ Million)
Figure 36. Asia Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
Figure 37. Asia Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
Figure 38. Asia Relapsing-Remitting Multiple Sclerosis Market Share by Region (2018-2033)
Figure 39. Japan Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. South Korea Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. China Taiwan Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Southeast Asia Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. India Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Australia Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Size YoY (2018-2033) & (US$ Million)
Figure 46. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Share by Type (2018-2033)
Figure 47. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Share by Application (2018-2033)
Figure 48. Middle East, Africa, and Latin America Relapsing-Remitting Multiple Sclerosis Market Share by Country (2018-2033)
Figure 49. Brazil Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 50. Mexico Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 51. Turkey Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Saudi Arabia Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Israel Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. GCC Countries Relapsing-Remitting Multiple Sclerosis Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Biogen Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 56. Novartis Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 57. Roche Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 58. Bayer HealthCare Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 59. Pfizer Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 60. Merck & Co., Inc Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 61. Sanofi Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 62. Teva Pharmaceutical Industries Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 64. Acorda Therapeutics Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 65. Actelion Pharmaceuticals (Johnson & Johnson) Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 66. AbbVie Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 67. CinnoVex Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 68. Extavia Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 69. Tysabr Revenue Growth Rate in Relapsing-Remitting Multiple Sclerosis Business (2018-2023)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries